Multiple myeloma (MM) predominantly affects older patients, and the management of this population remains particularly challenging. Older patients with newly diagnosed multiple myeloma (NDMM) represent a clinically heterogeneous population in whom chronological age alone inadequately reflects treatment tolerance and prognosis. Frailty and body composition abnormalities are increasingly recognized as relevant determinants of outcomes in non–transplant-eligible patients [1,2]. While sarcopenia has been associated with poor survival across several solid malignancies, its prognostic role inMM remains controversial [3].
No takes yet. Share an insight, caveat, or question.
Terlizzi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: